Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy

Blood (2014) 124 (21): 68.

https://doi.org/10.1182/blood.V124.21.68.68

Published: 2014

Journal Articles

The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability?

Yesim G. Dargaud, MDPhD, Marc Fouassier, MD, Sophie Ducastelle, MD, Philippe Moreau, MD, Charles Dumontet, MD PhD, Mauricette Michallet, MD PhD, Jean-Claude Bordet, Claude Negrier, MD PhD

Blood (2014) 124 (21): 2037.

https://doi.org/10.1182/blood.V124.21.2037.2037

Published: 2014

Journal Articles

Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium

Blood (2014) 124 (21): 2044.

https://doi.org/10.1182/blood.V124.21.2044.2044

Published: 2014

Journal Articles

A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus

Florence Magrangeas, Rowan Kuiper, BSc, Hervé Avet-loiseau, MD PhD, Wilfried Gouraud, Catherine Guérin, Henri Der Sakissian, Jérôme Suhard, Michel Attal, Pieter Sonneveld, MDPhD, Charles Dumontet, MD PhD, Philippe Moreau, Mark van Duin, PhD, Loic Campion, MD, Stephane Minvielle

Blood (2014) 124 (21): 2057.

https://doi.org/10.1182/blood.V124.21.2057.2057

Published: 2014

Journal Articles

Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics

Blood (2014) 124 (21): 2324.

https://doi.org/10.1182/blood.V124.21.2324.2324

Published: 2014

Journal Articles

The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis

Blood (2014) 124 (21): 3421.

https://doi.org/10.1182/blood.V124.21.3421.3421

Published: 2014

Journal Articles

Higher Percentage of CD34 + CD38 − Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predict Unsustained Complete Remission in AML

Adriana Plesa, MD, Mohamed Elhamri, PhD, Gilles Clapisson, Eve Mattei, Sophie Gazzo, PhD, Olivier Hequet, MD, Mauricette Michallet, MD, PhD, Charles Dumontet, MD, PhD, Xavier Thomas, MD

Blood (2012) 120 (21): 1485.

https://doi.org/10.1182/blood.V120.21.1485.1485

Published: 2012

Journal Articles

Single Nucleotide Polymorphisms in ABCB1 and CBR1 Predict Toxicity to R-CHOP Type Regimens in Patients with Diffuse Non Hodgkin's Lymphoma

Lars-Petter Jordheim, PhD, Vincent Ribrag, MD, Herve Ghesquieres, MD, PhD, Sophie Pallardy, Richard Delarue, MD, Herve Tilly, Corinne Haioun, MD, PhD, Fabrice Jardin, Gilles Salles, MD, Charles Dumontet, MD, PhD

Blood (2012) 120 (21): 1616.

https://doi.org/10.1182/blood.V120.21.1616.1616

Published: 2012

Journal Articles

Twist-1 Expression Represents a Novel Prognostic Factor in Chronic Myelogenous Leukemia.

Franck Emmanuel Nicolini, MD, PhD, Erika Cosset, MSc, Ghassan Hamdan, MSc, Sandrine Jeanpierre, BSc, Charles Dumontet, MD, PhD, Thibault Voeltzel, PhD, Alain Puisieux, PharmD, PhD, Véronique Maguer-Satta, PhD

Blood (2009) 114 (22): 2592.

https://doi.org/10.1182/blood.V114.22.2592.2592

Published: 2009

Journal Articles

Expression of the Chemokine Receptor CXCR4, CXCL12G801A Gene polymorphism and SDF1 Plasma Levels in B-Cell Chronic Lymphocytic Leukemia (B-CLL): Correlation with PBSC Mobilisation, Disease Characteristics and Outcome.

Adriana Plesa, MD, Gaetan Lesca, MD, Nathalie Dhedin, MD, Mohamad Sobh, Pharm.M, Anne S. Michallet, MD, PhD, Franck E. Nicolini, MD, PhD, Helene Merle-Beral, MD, PhD, Frederic Garban, MD, Veronique Leblond, MD, Karen Sagorny, Stephane Morisset, Alain Calender, MD, PhD, Charles Dumontet, MD, PhD, Michel Leporrier, MD, Laurent Sutton, MD, Mauricette Michallet, MD, PhD

Blood (2009) 114 (22): 2336.

https://doi.org/10.1182/blood.V114.22.2336.2336

Published: 2009

Journal Articles

The Bone Morphogenetic Protein (BMP)-4 Is Involved in the Regulation of Human Megakaryocytic Differentiation during Thrombopoietin Signaling.

Franck E Nicolini, MD, PhD, Sandrine Jeanpierre, BSc, Bastien Kaniewski, BSc, Charles Dumontet, MD, PhD, Ruth Rimokh, PhD, Alain Puisieux, Pharmd, PhD, Véronique Maguer-Satta, PhD

Blood (2008) 112 (11): 1339.

https://doi.org/10.1182/blood.V112.11.1339.1339

Published: 2008

Journal Articles

Long-Term Follow-up of Multiple Myeloma Patients Treated by Bortezomib (Velcade ® ): A Study on Efficacy, Tolerance, Survival and Time to Progression

Mauricette Michallet, MD, PhD, Mohamad Sobh, PhD, Quoc Hung Le, MD, Fiorenza Barraco, MD, Charles Dumontet, MD, PhD, Youcef Chelghoum, MD, Emmanuelle Nicolas-Virelizier, MD, Xavier Thomas, MD, Aline Praire, Claudiu Plesa, MD, Giovanna Cannas, MD, Franck Emmanuel Nicolini, MD, PhD, Jacques Troncy, MD

Blood (2008) 112 (11): 5197.

https://doi.org/10.1182/blood.V112.11.5197.5197

Published: 2008

Journal Articles

An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).

Ollivier Legrand, MD, Maria B. Vidriales, MD, Xavier Thomas, MD, Charles Dumontet, MD, Anne Vekhoff, MD, Rodica Morariu-Zamfir, MD, John Lambert, MD, Jesus F. San Miguel, MD, Jean-Pierre Marie, MD

Blood (2007) 110 (11): 1850.

https://doi.org/10.1182/blood.V110.11.1850.1850

Published: 2007

Journal Articles

Genetic Polymorphisms Correlated with Outcome in Multiple Myeloma Patients Receiving High Dose Melphalan.

Charles Dumontet, MD, PhD, Stefano Landi, PhD, Tony Reiman, MD, PhD, Adriana Plesa, MD, Ilaria Bellini, PhD, Roberto Barale, PhD, Linda M. Pilarski, MD, Sean Tavtigian, PhD, Troy Perry, BsC, Federica Gemignani, PhD

Blood (2007) 110 (11): 4746.

https://doi.org/10.1182/blood.V110.11.4746.4746

Published: 2007

Journal Articles

Correlation between MRD and Chimerism Kinetics in CLL Patients after Myeloablative and Non-Myeloablative Allogeneic Hematopoïetic Stem Cell Transplantation.

Adriana Plesa, MD, Quoc-Hung Le, MD, Daniela Revesz, MD, Xavier Thomas, MD PhD, Sophie Ducastelle, MD, Franck E. Nicolini, MD PhD, Anne-Sophie Michallet, MD, Isabelle Mollet, Valerie Dubois, PhD, Melisa Clark, Charles Dumontet, MD PhD, Nicole Raus, Mauricette Michallet, MD PhD

Blood (2007) 110 (11): 5048.

https://doi.org/10.1182/blood.V110.11.5048.5048

Published: 2007

Journal Articles

Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience.

Claudiu Plesa, MD, Quoc-Hung Le, MD, Youcef Chelghoum, MD, Mohamed Elhamri, PhD, Isabelle Tigaud, MD, Bruno Anglaret, MD, Sophie Ducastelle, MD, Marie-Claire Perrin, MD, Frank Nicolini, MD, Amine Belhabri, MD, Jacques Troncy, MD, Anne Thiebaut, MD, Daniela Revesz, MD, Eric Wattel, MD, Charles Dumontet, MD, Mauricette Michallet, MD, Xavier Thomas, MD

Blood (2007) 110 (11): 4352.

https://doi.org/10.1182/blood.V110.11.4352.4352

Published: 2007

Journal Articles

Prognostic Value of Immunophenotyping in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience.

Claudiu Plesa, MD, Youcef Chelghoum, MD, Adriana Plesa, MD, Mohamed Elhamri, PhD, Isabelle Tigaud, MD, Mauricette Michallet, MD, Charles Dumontet, MD, Xavier Thomas, MD

Blood (2007) 110 (11): 4353.

https://doi.org/10.1182/blood.V110.11.4353.4353

Published: 2007

Journal Articles

Identification of Genetic Markers for the Outcome of Patients with Acute Myeloid Leukemia Treated with Cytarabine.

Lars P. Jordheim, PharmD, Tu Nguyen, PhD, Xavier Thomas, MD, PhD, Charles Dumontet, MD, PhD, Sean V. Tavtigian, PhD

Blood (2007) 110 (11): 4294.

https://doi.org/10.1182/blood.V110.11.4294.4294

Published: 2007

Journal Articles

Genetic Polymorphisms Correlated with Outcome in Multiple Myeloma Patients Receiving High Dose Melphalan.

Charles Dumontet, MD, PhD, Stefano Landi, PhD, Tony Reiman, MD, Adriana Plesa, MD, Ilaria Bellini, PhD, Roberto Barale, PhD, Linda Pilarski, MD, Sean Tavtigian, PhD, Federica Gemignani, PhD

Blood (2006) 108 (11): 3085.

https://doi.org/10.1182/blood.V108.11.3085.3085

Published: 2006

Journal Articles

A Biomathematical Analysis of Immunophenotypic Characteristics in Patients with Acute Myeloblastic Leukemia.

Adriana Plesa, MD, Gabriela Ciuperca, PhD, Stephane Genieys, PhD, Veronique Louvet, PhD, Laurent Pujo-Menjouet, PhD, Arnaud Millaret, PharmD, Charles Dumontet, MD, Vitaly Volpert, PhD

Blood (2006) 108 (11): 4487.

https://doi.org/10.1182/blood.V108.11.4487.4487

Published: 2006

NARROW

TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy

The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability?

Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium

A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus

Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics

The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis

Higher Percentage of CD34 + CD38 − Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predict Unsustained Complete Remission in AML

Single Nucleotide Polymorphisms in ABCB1 and CBR1 Predict Toxicity to R-CHOP Type Regimens in Patients with Diffuse Non Hodgkin's Lymphoma

Twist-1 Expression Represents a Novel Prognostic Factor in Chronic Myelogenous Leukemia.

Expression of the Chemokine Receptor CXCR4, CXCL12G801A Gene polymorphism and SDF1 Plasma Levels in B-Cell Chronic Lymphocytic Leukemia (B-CLL): Correlation with PBSC Mobilisation, Disease Characteristics and Outcome.

The Bone Morphogenetic Protein (BMP)-4 Is Involved in the Regulation of Human Megakaryocytic Differentiation during Thrombopoietin Signaling.

Long-Term Follow-up of Multiple Myeloma Patients Treated by Bortezomib (Velcade ® ): A Study on Efficacy, Tolerance, Survival and Time to Progression

An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).

Genetic Polymorphisms Correlated with Outcome in Multiple Myeloma Patients Receiving High Dose Melphalan.

Correlation between MRD and Chimerism Kinetics in CLL Patients after Myeloablative and Non-Myeloablative Allogeneic Hematopoïetic Stem Cell Transplantation.

Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience.

Prognostic Value of Immunophenotyping in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience.

Identification of Genetic Markers for the Outcome of Patients with Acute Myeloid Leukemia Treated with Cytarabine.

Genetic Polymorphisms Correlated with Outcome in Multiple Myeloma Patients Receiving High Dose Melphalan.

A Biomathematical Analysis of Immunophenotypic Characteristics in Patients with Acute Myeloblastic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only